AxoGen Inc (NASDAQ:AXGN)
| 10.73 Delayed Data As of Sep 23 |  -0.26 / -2.36%Today’s Change | 6.87 Today|||52-Week Range 16.75 | +14.51% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $454.1M |
Company Description
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Contact Information
AxoGen, Inc. 13631 Progress Boulevard Alachua Florida 32615 |
Employees
Shareholders
| Other institutional | 44.53% |
| Mutual fund holders | 34.28% |
| Individual stakeholders | 25.21% |
Top Executives
| Karen L. Zaderej | Chairman, President & Chief Executive Officer |
| Mike Donovan | Vice President-Operations |
| Peter J. Mariani | Chief Financial Officer & Executive Vice President |
| Erick Wayne DeVinney | Vice President-Clinical & Translational Sciences |
| Ivica Ducic | Medical Director |
